Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients


Autoria(s): Fragoso, Maria Candida B. V.; Almeida, Madson Queiroz; Mazzuco, Tania L.; Mariani, Beatriz M. P.; Brito, Luciana P.; Goncalves, Talita Cardoso; Alencar, Guilherme A.; Lima, Lorena de O.; Faria, Andre M.; Bourdeau, Isabelle; Lucon, Antonio M.; Freire, Daniel S.; Latronico, Ana Claudia; Mendonca, Berenice B.; Lacroix, Andre; Lerario, Antonio M.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

21/10/2013

21/10/2013

2012

Resumo

Background: A recent microarray study identified a set of genes whose combined expression patterns were predictive of poor outcome in a cohort of adult adrenocortical tumors (ACTs). The difference between the expression values measured by qRT-PCR of DLGAP5 and PINK1 genes was the best molecular predictor of recurrence and malignancy. Among the adrenocortical carcinomas, the combined expression of BUB1B and PINK1 genes was the most reliable predictor of overall survival. The prognostic and molecular heterogeneity of ACTs raises the need to study the applicability of these molecular markers in other cohorts. Objective: To validate the combined expression of BUB1B, DLGAP5, and PINK1 as outcome predictor in ACTs from a Brazilian cohort of adult and pediatric patients. Patients and methods: BUB1B, DLGAP5, and PINK1 expression was assessed by quantitative PCR in 53 ACTs from 52 patients - 24 pediatric and 28 adults (one pediatric patient presented a bilateral asynchronous ACT). Results: DLGAP5 PINK1 and BUB1B PINK1 were strong predictors of disease-free survival and overall survival, respectively, among adult patients with ACT. In the pediatric cohort, these molecular predictors were only marginally associated with disease-free survival but not with overall survival. Conclusion: This study confirms the prognostic value of the combined expression of BUB1B, DLGAP5, and PINK1 genes in a Brazilian group of adult ACTs. Among pediatric ACTs, other molecular predictors of outcome are required.

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico from Sao Paulo, Brasil

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico from Sao Paulo, Brasil [CNPq 200069/2009-8]

Laboratory of Endocrine Pathophysiology, Centre de Recherche du CHUM (CRCHUM), Canada

Laboratory of Endocrine Pathophysiology, Centre de Recherche du CHUM (CRCHUM), Canada

Identificador

EUROPEAN JOURNAL OF ENDOCRINOLOGY, BRISTOL, v. 166, n. 1, supl. 1, Part 2, pp. 61-67, JAN, 2012

0804-4643

http://www.producao.usp.br/handle/BDPI/35242

10.1530/EJE-11-0806

http://dx.doi.org/10.1530/EJE-11-0806

Idioma(s)

eng

Publicador

BIOSCIENTIFICA LTD

BRISTOL

Relação

EUROPEAN JOURNAL OF ENDOCRINOLOGY

Direitos

restrictedAccess

Copyright BIOSCIENTIFICA LTD

Palavras-Chave #GENE #CARCINOMA #CLASSIFICATION #MALIGNANCY #MUTATION #ENDOCRINOLOGY & METABOLISM
Tipo

article

original article

publishedVersion